Items where authors include "Maughan, T"

Article

Corry, SM, McCorry, AMB, Lannagan, TRM et al. (31 more authors) (2022) Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer. Gut, 71 (12). pp. 2502-2517. ISSN 0017-5749

Love, SB, Cafferty, F, Snowdon, C et al. (33 more authors) (2022) Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials, 23 (1). p. 757. ISSN 1745-6215

Lee, RW, Danson, S, Elliot, M et al. (8 more authors) (2022) Importance of clinical research for the UK's 10-year cancer plan. The Lancet Oncology. ISSN 1470-2045

Mukherjee, S, Hurt, C, Radhakrishna, G et al. (17 more authors) (2021) Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. European Journal of Cancer, 153. pp. 153-161. ISSN 0959-8049

Hoorn, ST, Sommeijer, DW, Elliot, F et al. (12 more authors) (2021) Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone. British Journal of Cancer. ISSN 0007-0920

Sirinukunwattana, K, Domingo, E, Richman, SD orcid.org/0000-0003-3993-5041 et al. (21 more authors) (2021) Image-based consensus molecular subtype classification (imCMS) of colorectal cancer using deep learning. Gut, 70. pp. 544-554. ISSN 0017-5749

Willenbrock, F, Cox, CM, Parkes, EE et al. (10 more authors) (2021) Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer. British Journal of Cancer, 124 (3). pp. 581-586. ISSN 0007-0920

O’Cathail, SM, Davis, S, Holmes, J et al. (8 more authors) (2020) A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). Radiation Oncology, 15 (1). 151. ISSN 1748-717X

Strauss, VY, Shaw, R, Virdee, PS et al. (13 more authors) (2019) Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine +/- nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2). BMC Cancer, 19. ARTN 121. ISSN 1471-2407

Cross, W, Kovac, M, Mustonen, V et al. (53 more authors) (2018) The evolutionary landscape of colorectal tumorigenesis. Nature Ecology & Evolution, 2 (10). pp. 1661-1672. ISSN 2397-334X

Gollins, S, West, N orcid.org/0000-0002-0346-6709, Sebag-Montefiore, D orcid.org/0000-0002-5978-9259 et al. (11 more authors) (2018) A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS. British Journal of Cancer, 119 (6). pp. 697-706. ISSN 0007-0920

Alderdice, M, Richman, SD orcid.org/0000-0003-3993-5041, Gollins, S et al. (12 more authors) (2018) Prospective patient stratification into robust cancer‐cell intrinsic subtypes from colorectal cancer biopsies. Journal of Pathology, 245 (1). pp. 19-28. ISSN 0022-3417

Adams, R, Brown, E, Brown, L et al. (14 more authors) (2018) Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial. Lancet Gastroenterology and Hepatology, 3 (3). pp. 162-171. ISSN 2468-1253

Harrington, K, Hall, E, Hawkins, M et al. (11 more authors) (2017) Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET). Clinical Oncology, 29 (11). pp. 707-710. ISSN 0936-6555

Stewart, JP, Richman, S orcid.org/0000-0003-3993-5041, Maughan, T et al. (3 more authors) (2017) Standardising RNA profiling based biomarker application in cancer - the need for robust control of technical variables. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1868 (1). pp. 258-272. ISSN 0304-419X

Dunne, PD, Alderdice, M, O'Reilly, PG et al. (10 more authors) (2017) Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification. Nature Communications, 8. 15657. ISSN 2041-1723

Abbosh, C, Birkbak, NJ, Wilson, GA et al. (425 more authors) (2017) Phylogenetic ctDNA analysis depicts early stage lung cancer evolution. Nature, 545. pp. 446-451. ISSN 0028-0836

Seligmann, JF, Fisher, D, Smith, CG et al. (9 more authors) (2017) Investigating the poor outcomes of BRAF - mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials. Annals of Oncology, 28 (3). pp. 562-568. ISSN 0923-7534

Mukherjee, S, Hurt, CN, Gwynne, S et al. (15 more authors) (2017) NEOSCOPE: A randomized phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma. European Journal of Cancer, 74. pp. 38-46. ISSN 0959-8049

Salem, ME, Yin, J, Renfro, LA et al. (15 more authors) (2017) Rectal versus left-sided colon cancers: Clinicopathological differences observed in a pooled analysis of 4,182 patients enrolled to 8 clinical trials from the ARCAD database. Journal of Clinical Oncology, 35 (Supplement 4). p. 675. ISSN 0732-183X

Richman, SD, Adams, R, Quirke, P et al. (10 more authors) (2016) Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. Journal of Clinical Pathology, 69 (1). pp. 35-41. ISSN 0021-9746

Mukherjee, S, Hurt, CN, Gwynne, S et al. (16 more authors) (2015) NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. BMC Cancer, 15 (1). ARTN 48. ISSN 1471-2407

Middleton, G, Brown, S, Lowe, C et al. (17 more authors) (2013) A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). European Journal of Cancer, 49 (16). 3507 - 3516. ISSN 0959-8049

Seymour, MT, Brown, SR, Middleton, G et al. (18 more authors) (2013) Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. The Lancet Oncology, 14 (8). 749 - 759. ISSN 1470-2045

Conference or Workshop Item

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

Adams, R, Fisher, D, Graham, J et al. (13 more authors) (2021) Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial. In: 2021 ASCO Annual Meeting I, 04-08 Jun 2021, Online.

Yin, J, Cohen, R, Jin, Z et al. (16 more authors) (2020) Prognostic and predictive impact of primary tumor sidedness in first-line trials for advanced colorectal cancer: An analysis of 7,828 patients in the ARCAD database. In: 2020 Gastrointestinal Cancers Symposium, 23-25 Jan 2020, San Francisco, California.

Proceedings Paper

Brown, S, Van Herk, M, Chuter, R et al. (18 more authors) (2018) Advanced Radiotherapy Technologies Network in the UK (ART-NET) - focus on lung cancer. In: Lung Cancer. 16th Annual British Thoracic Oncology Group Conference 2018, 24-26 Jan 2018, Dublin, Ireland. Elsevier , S60-S60.

Richman, SD orcid.org/0000-0003-3993-5041, Adams, R, Brown, E et al. (14 more authors) (2017) FOCUS4: MAMS Trial Design in Action. Early Closure of FOCUS4-D (Pan-HER 1, 2 and 3 Inhibitor Versus Placebo) in Advanced Colorectal Cancer (aCRC) Patients, with Tumours Wildtype (WT) for KRAS, NRAS, bRAF and PIK3CA. In: Journal of Pathology. Belfast Pathology 2017: 10th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 20-23 Jun 2017, Belfast, Northern Ireland, UK. Wiley , S13-S13.

Adams, RA, Brown, E, Brown, L et al. (13 more authors) (2016) FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS. In: Annals of Oncology. 41st ESMO Congress (ESMO 2016), 07-11 Oct 2016, Copenhagen. Oxford University Publishing .

Seligmann, JF, Fisher, D, Smith, CG et al. (8 more authors) (2016) Exploring outcomes of RAS-mutant (RAS mut) advanced colorectal cancer (aCRC) treated with chemotherapy: Analysis from 2254 patients (pts) in randomised clinical trials (RCTs). In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 03-07 Jun 2016, Chicago, Il. American Society of Clinical Oncology .

Seligmann, JF, Fisher, D, Elliott, F et al. (8 more authors) (2015) Exploring the poor outcomes of BRAF mutant (BRAF mut) advanced colorectal cancer (aCRC): Analysis from 2,530 patients (pts) in randomized clinical trials (RCTs). In: Journal of Clinical Oncology. 2015 ASCO Annual Meeting, 29 May - 02 Jun 2015, Chicago, IL. American Society of Clinical Oncology .